28083-97-8

Upstream product

• 271-44-3 benzimidazole 
• 13035-61-5 1,2,3,5-tetraacetylribose 
• 144084-01-5 1-O-acetyl-2,3,5-tris-O-(p-chlorobenzoyl)-β-D-ribofuranose 
• 1053636-92-2 2-(2,3,5-tris-O-(p-chlorobenzoyl)-β-D-ribofuranosyl)indazole 

Relevant academic research and scientific papers

Transglycosylation of β-D-ribofuranosylindazoles

Irreversible, acid-catalyzed 2 → 1 transglycosylation reactions of fully acetylated β-D-ribofuranosylindazoles were studied applying HPLC analysis. Results so obtained support the intermolecular mechanism of transglycosylation via a 1,2-diglycosylindazole intermediate and are compared to those of the purine series.

Synthesis and enzymatic activity of some new purine ring system analogues of adenosine 3',5'-cyclic monophosphate

A series of novel adenosine 3',5'-cyclic monophosphate (cAMP) analogues, as well as their 6-deamino and 6-nitro derivatives, were synthesized where the purine ring was replaced by indazole, benzotriazole, and benzimidazole. The 3',5'-cyclic monophosphates of indazole and benzotriazole ribofuranosides, where the sugar-phosphate moiety is attached to the N-2 nitrogen atoms of the heterocycles, were also prepared. The biological efficiency of the analogues was tested by their ability to activate purified cAMP-dependent protein kinase I (PK-I) from rabbit skeletal muscle and cAMP- dependent protein kinase II (PK-II) from bovine heart. Each cyclic nucleotide is capable of activating both PK isozymes in half-maximum concentrations (K(a)) ranging from 2.0 · 10-8 to 4.8 · 10-6 M. The cyclic phosphate of N-1-β-D-ribofuranosylindazole (13) proved to be a very poor activator for both PK-I and PK-II, but when indazole binds by N-2 to ribose or when the hydrogen atom at C-4 is substituted by a nitro or amino group, activities of the analogues increase considerably. The activating potencies of benzotriazole derivatives are similar to that of cAMP, irrespective of the C- 4 substituents. The K(a)' values of cyclic nucleotides containing benzimidazole were found to be higher for PK-II than for PK-I; e.g. the activity of 4-nitro-1-β-D-ribofuranosylbenzimidazole 3',5'-cyclic monophosphate (32) is nearly 20 times as high for PK-II than for PK-I.